Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-04, Vol.384 (13), p.1227-1239
Hauptverfasser:	McInnes, Iain B, Anderson, Jaclyn K, Magrey, Marina, Merola, Joseph F, Liu, Yi, Kishimoto, Mitsumasa, Jeka, Slawomir, Pacheco-Tena, Cesar, Wang, Xin, Chen, Liang, Zueger, Patrick, Liu, John, Pangan, Aileen L, Behrens, Frank
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - adverse effects Adalimumab - therapeutic use Adult Adverse events Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis Arthritis, Psoriatic - drug therapy Dosage Dose-Response Relationship, Drug Double-Blind Method Drug dosages Enzyme inhibitors Female Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - adverse effects Heterocyclic Compounds, 3-Ring - therapeutic use Humans Janus kinase Janus Kinase Inhibitors - therapeutic use Joint diseases Least-Squares Analysis Liver Diseases - etiology Male Middle Aged Monoclonal antibodies Pain Patients Placebos Psoriasis Psoriatic arthritis Questionnaires Rheumatoid arthritis Statistical analysis TNF inhibitors Tumor necrosis factor-α
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There were hepatic disorders with upadacitinib.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2022516